Saniona AB Enters Licensing Agreement with Jazz Pharmaceuticals
Stockholm, August 25, 2025 — Saniona AB, a Danish biopharmaceutical company specializing in rare diseases, has recently entered into a licensing agreement with Jazz Pharmaceuticals for a drug candidate targeting epilepsy. This strategic move is part of Saniona’s ongoing efforts to expand its clinical-stage programs, which focus on conditions such as hypothalamic obesity, Prader-Willi syndrome, and rare neuropathic disorders.
The agreement was highlighted in a recent episode of Trading Direkt Healthcare, which also discussed Phase 2 results from an American competitor in the obesity sector. The news comes amid broader industry developments, including a new tariff decision from the United States. The decision sets a 15% tariff on the export of pharmaceuticals from Europe, potentially impacting the sector’s dynamics.
In addition to Saniona’s licensing deal, the healthcare sector has seen other significant activities. Bico and Ambea have released their interim reports, while Oncopeptides announced its second-quarter results alongside a capital raise of 150 million SEK. Furthermore, Kepler Cheuvreux has identified Novo Nordisk as its top pick in the sector, favoring it over Roche.
Saniona, listed on the Swedish Stock Exchange, has seen its share price close at 12.28 SEK on August 24, 2025, with a 52-week high of 12.92 SEK and a low of 2.505 SEK. The company’s market capitalization stands at 1.59 billion SEK, with a price-to-earnings ratio of 6.342.
For more information on Saniona’s offerings and developments, visit their website at www.saniona.com .